跳至主要内容
临床试验/NCT03475199
NCT03475199Unknown不适用

Evaluation of FabLife's Personalised Support Program Effectiveness in Sperm Quality Improvement in Men Suffering From Hypofertility

FabLife4 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2018年2月13日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
75
试验地点
4
主要终点
Sperm DNA fragmentation

研究概览

简要总结

FabLife is an interventional, prospective, multicentre, controlled study undertaken in metropolitan France.

The main objective is to evaluate the effect of FabLife personalised program over a period of 15 weeks on the improvement of spermatic DNA fragmentation in subfertile men compared to general dietary recommendations.

详细描述

More than 15 % of couples couldn't get pregnant after at least a year of unprotected intercourse.

The FabLife personalised program aims to improve sperm quality including sperm DNA fragmentation in subfertile men through:

  • A personalized dietary program based on patient's phenotype and genotype
  • A daily dietary supplement, developed in the context of male infertility

A total of 75 patients will be recruited:

  • 46 patients will benefit from the program,
  • 23 patients will form the control group.
  • 6 patients will not answer to all the criteria.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • All male volunteers aged 18 to 45 years belonging to a couple reporting an involuntary infertility greater than 12 months
  • Conventional spermatic parameters compatible with spontaneous pregnancy
  • Sperm Count> 5M / ml and
  • Progressive sperm mobility> 20%
  • Negative spermoculture
  • Fragmentation of sperm DNA> 20%
  • Patient able to understand dietary recommendations given in French, in writing and orally
  • Social insured patient receiving benefits from the French Social Security health branch
  • Patient with a mobile phone (iOS or Android) with internet access

排除标准

  • Patient diagnosed with severe oligospermia (<5 million spz / ejaculate)
  • Patient with BMI> 35 or <18.5
  • Patient with known and treated diabetes
  • Patient with known and treated lipid disorders
  • Patient with known and treated cardiovascular diseases
  • Patients with known and treated hypertension
  • Patients with known and treated dysthyroidism
  • Patients with known symptomatic varicocele
  • Patient with known inflammatory bowel diseases
  • Patient with renal failure diagnosed
  • Patient presenting a viral risk (HIV / Hepatitis B and C / ...) requiring support in a dedicated circuit
  • Patient unable to give informed consent
  • Minors and protected adults, vulnerable people
  • Patient participating in another clinical research study

研究组 & 干预措施

FabLife group

Experimental

Fablife personnalised support and telephone follow-up with a dietician.

干预措施: FabLife (Device)

Control group

No Intervention

General dietary recommendations.

结局指标

主要结局

Sperm DNA fragmentation

时间窗: 15 weeks

Difference in sperm DNA fragmentation from baseline to post-treatment

次要结局

  • Sperm motility(15 weeks)
  • Sperm concentration(15 weeks)
  • Semen volume(15 weeks)
  • Sperm morphology(15 weeks)
  • Total sperm count(15 weeks)
  • Semen quality(15 weeks)

研究者

发起方
FabLife
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

Evaluation of Personalised Support Program... | 临床试验